Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort.

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.

Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia.